Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.
Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. Cipollone F, et al. Among authors: muraro r. Circulation. 2003 Sep 2;108(9):1070-7. doi: 10.1161/01.CIR.0000086014.80477.0D. Epub 2003 Aug 11. Circulation. 2003. PMID: 12912808
Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.
Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, Ucchino S, Spigonardo F, Bajocchi G, Bei R, Muraro R, Artese L, Piattelli A, Chiarelli F, Cuccurullo F, Mezzetti A. Cipollone F, et al. Among authors: muraro r. Circulation. 2003 Mar 25;107(11):1479-85. doi: 10.1161/01.cir.0000056530.03783.81. Circulation. 2003. PMID: 12654603 Clinical Trial.
Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity.
Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, de Cesare D, Ucchino S, Spigonardo F, De Luca M, Muraro R, Bei R, Bucci M, Cuccurullo F, Mezzetti A. Cipollone F, et al. Among authors: muraro r. Circulation. 2004 Mar 30;109(12):1482-8. doi: 10.1161/01.CIR.0000121735.52471.AC. Epub 2004 Mar 22. Circulation. 2004. PMID: 15037537 Clinical Trial.
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes.
Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. Cuccurullo C, et al. Among authors: muraro r. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23. doi: 10.1161/01.ATV.0000249630.02085.12. Epub 2006 Oct 12. Arterioscler Thromb Vasc Biol. 2006. PMID: 17038636 Clinical Trial.
Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E.
De Caterina R, Cipollone F, Filardo FP, Zimarino M, Bernini W, Lazzerini G, Bucciarelli T, Falco A, Marchesani P, Muraro R, Mezzetti A, Ciabattoni G. De Caterina R, et al. Among authors: muraro r. Circulation. 2002 Nov 12;106(20):2543-9. doi: 10.1161/01.cir.0000038500.43292.d7. Circulation. 2002. PMID: 12427649 Clinical Trial.
86 results